Context . The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup was created to provide evidence and consensus-based recommendations on the use of extracorporeal treatments (ECTRs) in poisoning. Objectives. To perform a systematic review and provide clinical recommendations for ECTR in carbamazepine poisoning. Methods . After a systematic literature search, the subgroup extracted the data and summarized the fi ndings following a pre-determined format. The entire workgroup voted via a two-round modifi ed Delphi method to reach a consensus on voting statements, using a RAND/UCLA Appropriateness Method to quantify disagreement. Anonymous votes were compiled, returned, and discussed in person. A second vote determined the fi nal recommendations. Results . Seventy-four articles met inclusion criteria. Articles included case reports, case series, descriptive cohorts, pharmacokinetic studies, and in-vitro studies; two poor-quality observational studies were identifi ed, yielding a very low quality of evidence for all recommendations. Data on 173 patients, including 6 fatalities, were reviewed. The workgroup concluded that carbamazepine is moderately dialyzable and made the following recommendations:
Introduction
The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup comprises international experts representing diverse specialties and professional societies (Table 1) brought together to provide recommendations, based on evidence and consensus, for the use of extracorporeal treatments (ECTRs) in poisoning (www.extrip-workgroup.org). Rationale, background, objectives, complete methodology, and its fi rst recommendations have been published. 1 -6 The following text reviews the recommendations for carbamazepine.
Pharmacology
Carbamazepine has a structure similar to that of tricyclic antidepressants and is used for the treatment of bipolar disorder, neuropathic pain, hyperactivity, and seizure disorder. It inhibits the release of glutamate and similar neurotransmitters via blockage of presynaptic voltage-gated sodium channels in the central nervous system (CNS). It also blocks N-methyl D-aspartate and adenosine receptors. 7 Carbamazepine has a molecular weight of 236 Da and is highly bound to both albumin and alpha-1-acid glycoprotein (70 -80%), a percentage that does not appear to decrease signifi cantly in overdose: in one series of 4 patients with supratherapeutic concentrations, protein binding remained at 74 -82%, 8 while it decreased to 57% in another report. 9 Carbamazepine has a slow rate of dissolution, which results in erratic and incomplete absorption. 10, 11 It is highly lipophilic and distributes rapidly and extensively (volume of distribution ranges from 0.8 to 1.4 L/Kg).
Carbamazepine is extensively metabolized in the liver by the cytochrome P450 system. Only 1 -3% of the drug is excreted unchanged in the urine. Its primary metabolite, carbamazepine-10,11-epoxide, is 50% protein-bound and shares an equal anticonvulsant and toxic effect. 8 The nature of carbamazepine metabolism is complicated by the fact that it induces its own metabolism with chronic use; this auto-induction occurs relatively early in therapy, is dosedependent, and explains why carbamazepine-na ï ve patients usually exhibit more toxic symptoms at a given exposure than those who use it therapeutically.
Carbamazepine ' s half-life with initial dosing is reported to be 25 -65 h, which decreases to 12 -17 h with repeated or continued dosing. In overdose, much longer apparent half-lives are reported, 10,12 likely refl ecting ongoing absorption, impaired elimination, or some combination of both processes.
Overview of carbamazepine poisoning
Toxicity from carbamazepine overdose was fi rst described in 1967 13 and continues to be responsible for a large proportion of life-threatening cases among anticonvulsant poisonings.
Data from the US Poison Control Centers documented 4149 toxic carbamazepine exposures in 2012, 14% of which had at least a moderate effect. 115 Serum carbamazepine concentrations can be used to confi rm exposure. The therapeutic concentration range is 4 -12 mg/L (17 -51 μ mol/L) ( Table 2) ; signifi cant toxicity usually occurs over 40 mg/L (169 μ mol/L), 14 but also potentially at lower concentrations. 15 Neurologic symptoms including movement disorders, altered mental status, and seizures primarily characterize carbamazepine toxicity. Respiratory depression is common in severe overdose and can be complicated by concomitant aspiration. Cardiovascular effects include sinus tachycardia, hypotension, myocardial depression, and cardiac conduction disturbances; in rare cases, QRS complex prolongation, bundle branch block, Brugada-type patterns, atrioventricular block, and premature ventricular contractions are reported. 16 -18 Death has been reported due to refractory cardiovascular toxicity. 18 -20 Medication clumping and slow dissolution may occur with standard and sustained-release formulations. 21, 22 At high concentrations, carbamazepine exhibits anticholinergic proprieties, which delays gastrointestinal motility further prolonging absorption, with peak absorption sometimes documented over 100 hours post-ingestion. 12, 17, 23 Severely poisoned patients may suffer clinical deterioration after initial improvement or delayed onset toxicity that may result from rebounding or persistently high serum concentrations. Hyponatremia is a frequent adverse event during treatment, but is uncommon in cases of acute poisoning. Fatalities are extremely unusual, 24 but in one large cohort of 427 patients, 
overall mortality following was 13%; mean carbamazepine ingestion in lethal cases was 23.6 grams. 15 Most cases of toxicity can be successfully managed with appropriate supportive care including airway protection with endotracheal intubation, treatment of seizures with benzodiazepines, and correction of hypotension with fl uid challenges and vasopressors if needed. Hypertonic sodium bicarbonate can be used if evidence of sodium channel blockade is present on the electrocardiography. Gastrointestinal decontamination (e.g., single-dose activated charcoal) is indicated in those patients who present within 1 -2 h after ingestion and have no contraindications. 25 Multiple-dose activated charcoal (MDAC) increases elimination and improves clinical outcome in patients with carbamazepine overdose, 26 and is recommended for patients with life-threatening ingestions. 27 However, the use of MDAC can be limited by decreased bowel motility, 23,28 -30 or concerns over airway protection. Although no antidotes are available to reverse the effects of carbamazepine, isolated case reports have described successful treatment of cardiovascular toxicity with lipid resuscitation therapy. 31, 32 Extracorporeal life support has also been used, 17 but is technically complicated and not readily available in many hospital settings.
Recommendations from most consulted resources for ECTR in carbamazepine poisoning currently include the presence of life-threatening symptoms unresponsive to conventional treatment, 33 -37 or a contraindication to MDAC. 36 There are concerns about the effectiveness of ECTR as some articles state that its effect on clearance is not superior to that of MDAC. 37,38 Therapeutic plasma exchange is mentioned, but evidence is limited and its use is not recommended. 33, 34, 36 Oxcarbazepine has a molecular structure and clinical effects that are similar to carbamazepine; however, the scant data 39 cannot permit reliable extrapolation of the present recommendations to patients with oxcarbazepine poisoning.
Methodology
Pre-determined methodology incorporated guidelines from The Appraisal of Guidelines for Research and Evaluation (AGREE) 40 and Grades of Recommendation Assessment, Development and Evaluation (GRADE), 41 and is described in detail elsewhere. 2 The primary literature search was conducted on July 12th, 2012 in Medline, Embase, and Cochrane library (Systematic Reviews and CENTRAL).
The search strategy was as follows: A subgroup of EXTRIP completed the literature search, reviewed each article, extracted data, and summarized fi ndings. The level of evidence assigned to each clinical recommendation was determined by the subgroup and epidemiologist (Table 3) . Dialyzability was determined based on criteria listed in Table 4 . The potential benefi t of the procedure was weighed against its cost, availability, alternative treatments, and its related complications. All of this information was submitted to the entire workgroup for consideration, along with structured voting statements based on a pre-determined format.
The strength of recommendations was evaluated by a two-round modifi ed Delphi method for each proposed voting statement ( Fig. 1 ) and RAND/UCLA Appropriateness Method was used to quantify disagreement between voters. 42 Anonymous votes with comments were sent to the epidemiologist who then compiled and returned them to each participant. The workgroup met in person to exchange ideas and debate statements. A second vote was later submitted and these results were used in developing the core EXTRIP recommendations. The literature search was updated on October 1st 2014 following the same methodology as described above; the new articles and summarized data were submitted to every participant who then updated their votes. 
Results
Results of the literature search are presented in Fig. 2 . In the fi nal analysis, 74 studies were included: 2 observational studies (83 patients), 43,44 65 case reports or case series (71 patients), 8 -10,12,16,19,20,23,28 -30,45 -94,113,118 -120 4 pharmacokinetic (PK) studies (7 patients), 95 -98 1 descriptive cohort (12 patients), 99 and 2 in-vitro studies. 100, 101 No randomized controlled trials were identifi ed.
Clinical analysis
Two observational studies with clinical outcomes related to ECTR were found in the literature review; the fi rst comparing three different types of ECTR (hemodialysis vs charcoal hemoperfusion vs sorbent hemoperfusion), 44 and the second comparing low-fl ux hemodialysis to supportive care. 43 The former study showed a signifi cantly longer duration of artifi cial ventilation and worse neurological status at 6 and 12 hours in the group receiving hemodialysis; however, the groups were not comparable at baseline, the hemodialysis cohort being more severely poisoned. Thus, any conclusion on the impact of ECTR on the clinical outcome may have been biased by the presence of confounders. In the latter study, groups were also not comparable prior to the intervention (patients in the ECTR group had a higher carbamazepine concentration and a lower Glasgow Coma Score). Allocation was probably subject to confounding-by-indication (i.e., patients who had more signifi cant neurological fi ndings received hemodialysis). Despite 2 fatalities observed in the HD group, the aforementioned biases again preclude any interpretation on the clinical impact of ECTR. The remaining evidence of a clinical effect of ECTR was composed solely of case reports and case series, with absent control groups, multiple potential confounders, heterogeneous treatments, and defi nite publication bias. The quality of evidence for all recommendation statements would, therefore, be graded as " very low " . 41 An aggregate description of case reports is presented in Table 5 . The median carbamazepine ingestion and peak Blood purifi cation in carbamazepine poisoning 997 concentration were 20.9 grams and 46.2 mg/L, respectively. None of the patients were asymptomatic; all had a varying degree of impairment of consciousness, while several experienced either respiratory depression, hypotension, seizures, conduction abnormalities, or a combination of these. Overall, 6 fatalities were described and appeared consequential to carbamazepine exposure instead of the ECTR itself. 19, 20, 43, 90, 99 Although the evidence may be determined as anecdotal, most of the patients who received ECTR (especially hemoperfusion or hemodialysis) appeared to improve rapidly after initiation of the procedure and had an uneventful outcome, including some patients who reportedly ingested doses greater than 500 mg/kg, 29, 30, 60, 62, 64, 72, 85 and who had concentrations over 60 mg/L (254 μ mol/L). 8, 12, 16, 51, 60, 66, 70, 75, 79, 82, 88, 120 Patients receiving less effective treatments, such as continuous renal replacement therapies (CRRT) and peritoneal dialysis, improved less quickly, over days. 56, 59, 85, 118 Reported complications of ECTRs were almost exclusively associated with hemoperfusion and included hypocalcemia, hypotension, and thrombocytopenia. 10, 12, 23, 28, 51, 62, 70, 74, 76, 77, 79, 91, 92 Bleeding or a drop in hemoglobin was documented in three cases. 50, 70, 113 Toxicokinetic analysis Carbamazepine is a small molecule and has a relatively low volume of distribution (V D ). Protein binding at therapeutic plasma concentration is signifi cant and decreases slightly, if at all, in overdose. 8, 9 Hemoperfusion would, therefore, be the technique most likely to be effi cient. 102, 103 Averaged kinetic parameters for all ECTRs (Table 6) , kinetic grading of individual patients (Table 7) , as well as comparative studies using both hemoperfusion and hemodialysis, 44, 64, 87 suggest that hemoperfusion is the most effective technique for removing carbamazepine; both resin and charcoal hemoperfusion have been used successfully with high clearances in this context, although these are sometimes limited by early saturation of the cartridges, an inconsistent fi nding. 44, 53, 54, 66, 72, 74, 78, 79 Nevertheless, carbamazepine appears amenable to removal with other ECTRs, such as hemodialysis and hemofi ltration that are not commonly assumed to remove protein-bound molecules. 104 The median clearances for The determination of carbamazepine dialyzability is supported by several recent publications, 59,63 -65,75,76,97,119 a number of which collected it directly in dialysate or effl uent fl uid, which is the preferred method to assess dialyzability. 2, 105 The literature also included a prospective case series of carbamazepine pharmacokinetics in four end-stage renal disease subjects; although the technical characteristics of the ECTR used in the study are outdated (cuprophane fi lter and low blood fl ow), clearance during hemodialysis was twice that calculated endogenously. 97 Based on the criteria defi ned in Table 4 , 2 most of the cases reviewed for carbamazepine would qualify as either " dialyzable " or " moderately dialyzable. " The workgroup preferred a conservative grading and, therefore, agreed with the following statement: carbamazepine is moderately dialyzable (level of evidence ϭ B).
The data on dialyzability of the metabolite carbamazepine-10,11-epoxide are not as abundant as those for carbamazepine. However, its protein binding is less than that of carbamazepine (50%), which suggests at least comparable dialyzability. This hypothesis is supported by a few reports. 8, 28, 53, 60 Comparison of ECTR with MDAC MDAC accelerates the elimination of carbamazepine and is currently supported by the latest position statement jointly published by EAPCCT and AACT. 27 In the rationale, it is suggested that MDAC provides toxicokinetic advantages similar to those of ECTR. 116 -117 The comparison of carbamazepine toxicokinetics in an individual using different techniques is particularly challenging because its elimination in overdose may follow zero-order or fi rst-order elimination kinetics at different concentrations. Nevertheless, in patients where comparative toxicokinetic estimations (from half-life, clearance, or graphical data plots) were possible, ECTR was superior to MDAC in enhancing elimination of carbamazepine. 9, 23, 64, 66, 69, 72, 76 In one study in particular, carbamazepine ' s elimination constant (Ke) was 0.009/h during endogenous metabolism, 0.039/h during MDAC, and 0.059/h during hemodialysis. 9
Recommendations (Table 8)
General statement: ECTR is suggested in severe 1.
carbamazepine
poisoning (2D)
Rationale : Carbamazepine is a widely used pharmaceutical and has a narrow therapeutic index. Although rarely fatal, poisoning can cause serious clinical effects and result in a prolonged hospital stay. The data suggesting that rapidly reducing carbamazepine concentration by ECTR may lower morbidity are unavailable, but can be extrapolated from the data on MDAC. 26 Despite the absence of high-quality evidence, the workgroup considered the following arguments:
The risk of prolonged coma with mechanical ventilation • is not benign.
Complications associated with ECTR are infrequent and • usually mild. There is a theoretical concern of provoking withdrawal seizures in a patient with an underlying seizure disorder. There are no life-saving antidotes in carbamazepine poi-• soning. MDAC may enhance its clearance, but the effect is incomplete and often limited by ileus or concerns of pulmonary aspiration in an unprotected airway. ECTR can achieve rapid and substantial removal of • carbamazepine. 69,75 For these reasons, the workgroup considered overall that ECTR is worth the risks, costs, and relative uncertainty in patients with severe carbamazepine poisoning, as defi ned by the conditions below. Most participants (21/28) supported the use of ECTR (voting score, Ն 7), while the remainder (7/28) had a neutral opinion (voting score, 4 -6). While advocating ECTR, the workgroup stated that, in this context, it was unlikely to substantially decrease mortality (as carbamazepine-related fatalities are uncommon) or to avoid irreversible injury (such as it might for blindness in methanol poisoning); instead, ECTR would expectantly be benefi cial to reduce short-term morbidity (related to severe hypotension and recurrent seizures) and avoid complications related to prolonged respiratory insuffi ciency and coma (e.g., ventilator associated pneumonia, pulmonary emboli, and immobilization). Most participants supported the use of ECTR to potentially decrease mechanical ventilation time, intensive care unit (ICU)-related costs, and length of stay in the ICU. 46 Nevertheless, some participants also considered that active supportive care alone with or without MDAC was suffi cient or even preferable to using ECTR in severe carbamazepine poisoning. Rationale: The workgroup proposed that indications for initiation of ECTR in any poisoning should be based on criteria which include exposure (e.g., ingestion, contact, or inhalation), measurement of poison in body fl uids, para-clinical tests, and clinical symptoms and signs. The workgroup agreed that there were too many uncertainties related to the ingested dose to initiate ECTR simply on this information alone. Since serum carbamazepine concentrations are available in the majority of centers, the decision to initiate ECTR should be delayed until confi rmation of a toxic exposure becomes possible. Supportive measures, proper gastrointestinal decontamination, and MDAC (as described above) are preferred management for patients presenting after an acute exposure and have no other indication for ECTR. Obviously, if the ingestion history is confi rmed and the clinician suspects that major toxicity might ensue (i.e., ingestion Ͼ 100 mg/kg and especially Ͼ 20 g 15, 106 ), early communication with a nephrologist and disposition for possible ECTR are warranted.
Monitoring of serum carbamazepine concentrations can confi rm exposure and data can be obtained in a time frame relevant enough to guide clinical decisions. Symptoms appear to be more severe at concentrations greater than 40 mg/L (169 μ mol/L), 14,24 although clear correlation with mortality is uncertain. 15 Nevertheless, the workgroup suggested that isolated elevated carbamazepine concentrations in asymptomatic patients did not warrant ECTR; although several participants stated that some consideration for ECTR should be made at carbamazepine concentrations over 45 mg/L (190 μ mol/L), no formal consensus could be obtained at this or any other cutoff. None of the patients identifi ed in our literature review were asymptomatic. Although prophylactic ECTR (i.e., ECTR before the appearance of symptoms) can be considered in poisons where irreversible or life-threatening clinical toxicity can be expected (e.g., paraquat and methanol), the workgroup did not endorse this approach for carbamazepine. The workgroup recognized that children may exhibit more clinical toxicity at an equivalent concentration, perhaps due to a different metabolism and accumulation of the epoxide metabolite, 107 -109 but again the decision to initiate ECTR in this population should be guided on symptoms rather than on an arbitrary serum carbamazepine concentration threshold. Seizures and dysrhythmias can both follow carbamazepine poisoning and are usually associated with a poorer prognosis. 15 Obviously, these should be managed with usual supportive therapy as described above. Carbamazepine-induced seizures are possibly induced by accumulation of the epoxide metabolite and are usually singular events when they occur. In the unlikely case that seizures become intractable and unresponsive to conventional therapy, ECTR was strongly recommended by the workgroup. This was also the case for life-threatening dysrhythmias; although the workgroup acknowledged that this was a rare occurrence, 24 there is some evidence to suggest benefi t from rapid carbamazepine removal in this context. 9, 12, 16 There was less support for ECTR in carbamazepineinduced coma because this condition was not seen in itself to be as concerning as the above other symptoms. Unlike valproic acid poisoning, where cerebral edema can occur, coma in carbamazepine poisoning is not caused by structural or morphological changes in the CNS. Although not necessarily associated with a poor outcome, 15,24 coma can be particularly prolonged in massive ingestions and might necessitate protracted mechanical ventilation, in which case there was more agreement to initiate ECTR. Although diffi cult to estimate clinically, a protracted course can be anticipated in patients with large ingestions, delayed-release preparations, extremely high concentrations, and those who are na ï ve to carbamazepine (absence of auto-induction in patients on chronic therapy).
Lesser symptoms such as ataxia, ileus, confusion, nystagmus, and mild cardiac conduction defects are associated with a favorable outcome 15 and were not considered suffi ciently severe to justify ECTR.
Increasing carbamazepine concentrations are usually refl ective of prolonged absorption which can be managed by MDAC. The inability to administer MDAC was not considered by itself as an indication for ECTR but would reduce its decision threshold for initiation in toxic patients. However, in cases where MDAC is contraindicated, unavailable, could not be adequately performed or unable to reduce carbamazepine concentrations, and with evidence of clinical toxicity, ECTR was recommended by the workgroup. This was also the case in patients who fail supportive therapy. Rationale : The workgroup agreed that hemodialysis is the preferred modality of ECTR in carbamazepine poisoning. Although historical preference was given to intermittent hemoperfusion, because of its theoretical advantage of clearing protein-bound poisons such as carbamazepine, there are several arguments that now favor the use of intermittent hemodialysis:
Recent data suggest that hemodialysis is almost as • effective as hemoperfusion 9,64,87 due to improved clearances provided by newer high-fl ux and high-effi ciency synthetic membranes compared with those provided by older less effi cient cuprophane dialyzers. Present-day catheters can also achieve blood fl ows during hemodialysis up to 400 mL/min, while blood fl ow for several hemoperfusion cartridges remains limited to 300 -350 mL/min 68 because of the risk of hemolysis. 110 Intermittent hemodialysis is the favored treatment for • maintenance dialysis in patients with end-stage kidney disease (ESRD) and acute kidney injury (AKI) worldwide; therefore, this is the most available modality. Meanwhile, hemoperfusion cartridges are of limited availability in many parts of the world, as is the accessibility to online hemofi ltration. Therefore, the travel distance to a hemodialysis center for a poisoned patient would likely be minimized. 60, 76, 85, 113, 119 and, as such, are considered to be inferior modalities by EXTRIP and only advocated if hemodialysis is not available (due to technical or staffi ng reasons in critical care settings). Continuous techniques are usually better tolerated hemodynamically than intermittent techniques, although this is mostly true in cases where net fl uid removal is necessary, which would be an unusual requirement in carbamazepine poisoning. Peritoneal dialysis, 59 exchange transfusion, 95 and plasma exchange 63 do not offer comparable results to hemodialysis or hemoperfusion, as expected, 112 and are not currently recommended. Limited data for albumin-enhanced techniques are available, 46, 73, 113, 119 but these procedures are extremely costly and have not shown superiority to either hemoperfusion or hemodialysis; in one study, the addition of 20% albumin in the dialysate increased clearance by 24%. 119 Whatever the technique is used, operating ECTR characteristics should be optimized to maximize removal, that is, high blood and dialysate fl ow rates, 104, 114, 119 high surface area fi lters, and longer duration of ECTR. 104 Miscellaneous: MDAC therapy should be continued 5.
during
ECTR (1D)
Rationale: MDAC may enhance elimination of carbamazepine, may reduce toxicity in carbamazepine-poisoned patients, 26 and is currently recommended for this indication by various toxicology societies. 27 The workgroup supported MDAC during ECTR in patients who did not present contraindications to its use. Its effect on elimination would likely be additive to ECTR and should be used whenever the airway is protected, either by the patient ' s own refl exes or an endotracheal tube. 9,64,72
Conclusion
Here, the EXTRIP workgroup presents its recommendations for ECTRs in carbamazepine poisoning. The evidence suggests that elimination enhancement with intermittent hemodialysis or hemoperfusion is superior to MDAC. In the large majority of patients with toxic carbamazepine exposures, supportive management appears suffi cient. However, in severe cases, the group supported the use of ECTR on the basis that advantages superseded costs and risks associated with the procedures, despite an absence of robust clinical studies.
